NanoViricides, Inc.: Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
SHELTON, CO / ACCESSWIRE / July 6, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that the clinical trial…